Stromal Remodeling Emerges as a Defining Feature of Unicentric Castleman Disease
Castleman disease has long posed a diagnostic problem because enlarged lymph nodes can resemble a range of inflammatory and reactive conditions while the underlying biology remains hard to pin down on routine histology. This study moves the focus away from the hematopoietic compartment and toward the lymph node stroma, where the most striking differences emerged in unicentric Castleman disease compared with non-specific inflammatory lymphadenopathies.
Single-cell and spatial transcriptomic profiling showed that hematopoietic cells were largely similar across the groups. The sharper signal came from the stromal compartment, where lymph nodes from unicentric disease carried a marked increase in vascular smooth muscle cells and a broader rise in stromal signaling activity. In practical terms, the architecture that supports and organizes the node appears to be altered in a way that routine pathology can miss.
One sentence captures the central finding: the stromal compartment, not the immune cell compartment, carried the strongest disease signature.
Why Vascular Smooth Muscle Cells Stand Out in the Node
The enrichment of vascular smooth muscle cells in affected lymph nodes is biologically persuasive. These cells sit close to blood vessel walls and participate in vascular tone, structural support, and tissue remodeling. When they accumulate in excess or appear in an abnormal spatial pattern, they can reflect a local repair or remodeling program rather than a simple inflammatory infiltrate. In Castleman disease, where the node is already distorted by abnormal growth and inflammation, this stromal expansion offers a plausible marker of the tissue-level process driving the lesion.
The study did not find dramatic compositional or transcriptional divergence among hematopoietic cells, which makes the stromal compartment even more important diagnostically. In diseases with mixed inflammatory features, pathologists often rely on subtle morphologic cues and a pattern-recognition approach. Here, the tissue support system itself carried the most useful information, suggesting that the disease biology is embedded in the node’s structural framework.
That shift matters because it explains why some lymph nodes remain histologically ambiguous even when the clinical picture suggests Castleman disease. If the dominant abnormality is stromal, then a pathology workflow centered only on immune infiltrates may undercall the lesion or misclassify it as generic inflammation.
Spatial and Single-Cell Data Point to a Diagnostic Signature
The investigators used both single-cell and spatial transcriptomics, a combination that is well suited to a disease defined by tissue architecture. Single-cell profiling captures which cell types are present and how they are transcriptionally altered, while spatial methods preserve the location of those cells inside the lymph node. Together, these approaches allowed the team to show not only that VSMCs were increased, but also that stromal signaling was broadly activated in unicentric disease.
A generalized linear model strengthened the practical value of the finding. When the model was used to distinguish histologically indeterminate lymph nodes resembling unicentric Castleman disease from non-specific inflammation, stromal cell composition outperformed hematopoietic composition. This is an important diagnostic message for routine practice: the cell populations most useful for classification were not the ones traditionally emphasized in inflammatory pathology.
The model’s performance was then supported by immunohistochemistry. Staining for CD146, also known as Melanoma Cell Adhesion Molecule or MCAM, helped discriminate unicentric Castleman disease from other causes of lymphadenopathy. In effect, a stromal marker linked to vascular smooth muscle identity provided a pathologic handle on a disease that otherwise resists easy categorization.
What the CD146 Signal Means at the Bedside
CD146 is not being proposed here as a standalone clinical answer, and the study does not claim that a single stain can replace expert pathology review. Even so, the marker offers a concrete way to operationalize the transcriptomic signal in tissue sections. For a pathologist faced with a lymph node that sits between specific disease and non-specific inflammation, an expanded stromal stain panel could improve confidence in classification.
The biological logic is straightforward. If unicentric Castleman disease is marked by a remodeling of the stromal scaffold, then a vascular smooth muscle-associated marker such as CD146 should track with that process. The appearance of that signal in immunohistochemistry aligns with the transcriptomic data and makes the observation more than a sequencing artifact.
This is also where diagnostic stratification becomes more relevant than simple labeling. A node with a stromal pattern consistent with unicentric Castleman disease may warrant a different level of clinical attention than a node read as reactive inflammation, particularly when the pathologic distinction influences downstream workup, surveillance, and consideration of treatment.
Pathology That Reframes Disease Biology
The study’s larger contribution is conceptual. Castleman disease has been difficult to understand because the inflammatory surface of the disorder can obscure the tissue compartments where the core abnormality resides. By showing that stromal cells, especially vascular smooth muscle cells, carry the clearest signal, the investigation reframes unicentric Castleman disease as a disorder of lymph node organization rather than only immune activation.
That perspective could influence how future diagnostic tools are built. Algorithms that rely heavily on hematopoietic signatures may miss the most informative biology, while stromal-aware models may better capture the disease state. Spatial transcriptomics, in particular, appears well matched to a disorder where cell identity and tissue placement both matter.
The findings also raise a practical question for pathology labs: how much of the current diagnostic uncertainty stems from under-sampling the stromal compartment? If the answer is substantial, then adding stromal markers and structural analytics could close a real gap between morphologic suspicion and molecular confirmation.
Limits of the Signal and the Work Still Ahead
This was a focused comparison of lymph nodes from unicentric Castleman disease and non-specific inflammatory lymphadenopathies, not a broad survey of every Castleman subtype or every mimicking disorder. The diagnostic promise therefore needs careful validation in larger and more diverse cohorts before it can be treated as routine practice. The study also points to a signature, not a treatment target, so the immediate clinical use is diagnostic rather than therapeutic.
Even with those boundaries, the message is hard to ignore. Stromal abundance, especially the rise in vascular smooth muscle cells, appears to be a hallmark of unicentric Castleman disease, and CD146 immunostaining may help surface that biology at the microscope.
The remaining challenge is to determine how widely this stromal signature applies across the Castleman spectrum and whether it can be standardized into pathology workflows that are reliable outside specialized research settings.